Inflammatory risk factors, biomarkers and associated therapy in ischaemic stroke

Charles C. Esenwa, Mitchell S. Elkind

Research output: Contribution to journalReview article

45 Citations (Scopus)

Abstract

Proinflammatory conditions, including acute and chronic infections, have been associated with an increased risk of stroke. The risk of stroke is increased by both the acute and chronic phases of a wide spectrum of proinflammatory conditions, suggesting that the association is related to activation of the inflammatory response rather than the condition itself. Different inflammatory mechanisms probably influence the risk of different stroke subtypes. This hypothesis is supported by observations that high levels of various immune system markers and acute phase reactants in otherwise healthy individuals have also been associated with ischaemic stroke subtypes. C-reactive protein, IL-6 and lipoprotein-associated phospholipase A2 are some of the inflammatory markers that have been associated with stroke risk and prognosis. Multiple epidemiological studies have demonstrated that these markers are associated with the risk of stroke, but the value of these markers in a clinical setting has not yet been proven. Further research is needed to determine whether immune system modulators can lower the risk of stroke in individuals with elevated concentrations of inflammatory markers. Here, we review the association between infection, systemic inflammation, and ischaemic stroke, and discuss the currently recommended preventive methods to decrease the risk of stroke associated with systemic inflammation.

Original languageEnglish (US)
Pages (from-to)594-604
Number of pages11
JournalNature Reviews Neurology
Volume12
Issue number10
DOIs
StatePublished - Oct 1 2016
Externally publishedYes

Fingerprint

Biomarkers
Stroke
Therapeutics
Immune System
1-Alkyl-2-acetylglycerophosphocholine Esterase
Inflammation
Acute-Phase Proteins
Infection
C-Reactive Protein
Epidemiologic Studies
Interleukin-6
Research

ASJC Scopus subject areas

  • Clinical Neurology
  • Cellular and Molecular Neuroscience

Cite this

Inflammatory risk factors, biomarkers and associated therapy in ischaemic stroke. / Esenwa, Charles C.; Elkind, Mitchell S.

In: Nature Reviews Neurology, Vol. 12, No. 10, 01.10.2016, p. 594-604.

Research output: Contribution to journalReview article

@article{9a992d0adab340db9da533b47220bcf5,
title = "Inflammatory risk factors, biomarkers and associated therapy in ischaemic stroke",
abstract = "Proinflammatory conditions, including acute and chronic infections, have been associated with an increased risk of stroke. The risk of stroke is increased by both the acute and chronic phases of a wide spectrum of proinflammatory conditions, suggesting that the association is related to activation of the inflammatory response rather than the condition itself. Different inflammatory mechanisms probably influence the risk of different stroke subtypes. This hypothesis is supported by observations that high levels of various immune system markers and acute phase reactants in otherwise healthy individuals have also been associated with ischaemic stroke subtypes. C-reactive protein, IL-6 and lipoprotein-associated phospholipase A2 are some of the inflammatory markers that have been associated with stroke risk and prognosis. Multiple epidemiological studies have demonstrated that these markers are associated with the risk of stroke, but the value of these markers in a clinical setting has not yet been proven. Further research is needed to determine whether immune system modulators can lower the risk of stroke in individuals with elevated concentrations of inflammatory markers. Here, we review the association between infection, systemic inflammation, and ischaemic stroke, and discuss the currently recommended preventive methods to decrease the risk of stroke associated with systemic inflammation.",
author = "Esenwa, {Charles C.} and Elkind, {Mitchell S.}",
year = "2016",
month = "10",
day = "1",
doi = "10.1038/nrneurol.2016.125",
language = "English (US)",
volume = "12",
pages = "594--604",
journal = "Nature Reviews Neurology",
issn = "1759-4758",
publisher = "Nature Publishing Group",
number = "10",

}

TY - JOUR

T1 - Inflammatory risk factors, biomarkers and associated therapy in ischaemic stroke

AU - Esenwa, Charles C.

AU - Elkind, Mitchell S.

PY - 2016/10/1

Y1 - 2016/10/1

N2 - Proinflammatory conditions, including acute and chronic infections, have been associated with an increased risk of stroke. The risk of stroke is increased by both the acute and chronic phases of a wide spectrum of proinflammatory conditions, suggesting that the association is related to activation of the inflammatory response rather than the condition itself. Different inflammatory mechanisms probably influence the risk of different stroke subtypes. This hypothesis is supported by observations that high levels of various immune system markers and acute phase reactants in otherwise healthy individuals have also been associated with ischaemic stroke subtypes. C-reactive protein, IL-6 and lipoprotein-associated phospholipase A2 are some of the inflammatory markers that have been associated with stroke risk and prognosis. Multiple epidemiological studies have demonstrated that these markers are associated with the risk of stroke, but the value of these markers in a clinical setting has not yet been proven. Further research is needed to determine whether immune system modulators can lower the risk of stroke in individuals with elevated concentrations of inflammatory markers. Here, we review the association between infection, systemic inflammation, and ischaemic stroke, and discuss the currently recommended preventive methods to decrease the risk of stroke associated with systemic inflammation.

AB - Proinflammatory conditions, including acute and chronic infections, have been associated with an increased risk of stroke. The risk of stroke is increased by both the acute and chronic phases of a wide spectrum of proinflammatory conditions, suggesting that the association is related to activation of the inflammatory response rather than the condition itself. Different inflammatory mechanisms probably influence the risk of different stroke subtypes. This hypothesis is supported by observations that high levels of various immune system markers and acute phase reactants in otherwise healthy individuals have also been associated with ischaemic stroke subtypes. C-reactive protein, IL-6 and lipoprotein-associated phospholipase A2 are some of the inflammatory markers that have been associated with stroke risk and prognosis. Multiple epidemiological studies have demonstrated that these markers are associated with the risk of stroke, but the value of these markers in a clinical setting has not yet been proven. Further research is needed to determine whether immune system modulators can lower the risk of stroke in individuals with elevated concentrations of inflammatory markers. Here, we review the association between infection, systemic inflammation, and ischaemic stroke, and discuss the currently recommended preventive methods to decrease the risk of stroke associated with systemic inflammation.

UR - http://www.scopus.com/inward/record.url?scp=84989253891&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84989253891&partnerID=8YFLogxK

U2 - 10.1038/nrneurol.2016.125

DO - 10.1038/nrneurol.2016.125

M3 - Review article

C2 - 27615422

AN - SCOPUS:84989253891

VL - 12

SP - 594

EP - 604

JO - Nature Reviews Neurology

JF - Nature Reviews Neurology

SN - 1759-4758

IS - 10

ER -